SMTL ID : 8dnj.2 (2 other biounits)

Crystal structure of human KRAS G12C covalently bound with AstraZeneca WO2020/178282A1 compound 76

Coordinates

PDB Format Compare

Method

X-RAY DIFFRACTION 1.81 Å

Oligo State

monomer

Ligands

1 x MG: MAGNESIUM ION(Non-covalent)

MG.1: 3 residues within 4Å: Chain A: S.32, D.72 Ligands: GDP.2 5 PLIP interactions: 1 interactions with chain A, 4 Ligand-Water interactions Metal complexes: A:S.32, H2O.1, H2O.1, H2O.1, H2O.1

1 x GDP: GUANOSINE-5'-DIPHOSPHATE(Non-covalent)

GDP.2: 20 residues within 4Å: Chain A: A.26, C.27, G.28, V.29, G.30, K.31, S.32, A.33, F.43, V.44, D.45, Y.47, N.131, K.132, D.134, L.135, S.160, A.161, K.162 Ligands: MG.1 19 PLIP interactions: 19 interactions with chain A Hydrogen bonds: A:G.28, A:V.29, A:G.30, A:K.31, A:S.32, A:A.33, A:V.44, A:Y.47, A:N.131, A:K.132, A:K.132, A:A.161, A:K.162 Water bridges: A:S.32, A:S.32 Salt bridges: A:K.31, A:D.134 pi-Stacking: A:F.43, A:F.43

1 x U4U: 1-[(5S,9P,12aR)-9-(2-chloro-6-hydroxyphenyl)-8-ethynyl-10-fluoro-3,4,12,12a-tetrahydro-6H-pyrazino[2,1-c][1,4]benzoxazepin-2(1H)-yl]propan-1-one(Covalent)

U4U.3: 16 residues within 4Å: Chain A: V.24, G.25, C.27, K.31, P.49, T.73, A.74, G.75, E.78, Y.79, R.83, M.87, H.110, Y.111, Q.114, I.115 7 PLIP interactions: 7 interactions with chain A Hydrophobic interactions: A:Y.111, A:Q.114, A:Q.114 Hydrogen bonds: A:K.31, A:T.73, A:R.83 Water bridges: A:R.83

Links

RCSB   PDBe   PDBe-KB   PDBj   PDBsum   CATH   PLIP

Citation

Zhu, K. et al., Modeling receptor flexibility in the structure-based design of KRAS G12C inhibitors. J.Comput.Aided Mol.Des. (2022)

Release Date

2022-08-17

Peptides

Isoform 2B of GTPase KRas: A

SMTL:PDB

SMTL Chain Id:
PDB Chain Id:

A
B

Isoform 2B of GTPase KRas

Related Entries With Identical Sequence